G. Morelli

发表

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

S. Zeuzem, D. Nelson, M. Sulkowski, 2016, Gut.

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection

N. Terrault, D. Nelson, J. Reeves, 2018, Scientific Reports.

All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database

M. Manns, A. Lok, K. Reddy, 2017, Alimentary pharmacology & therapeutics.

Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy.

A. Lok, K. Reddy, D. Nelson, 2019, Gastroenterology.

Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1

Tara L. Kieffer, V. Garg, D. Nelson, 2015 .

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

P. Pang, D. Wyles, E. Svarovskaia, 2015, Hepatology.

Rapid-sequence endoscopic management of posttransplant anastomotic biliary strictures.

Jen-Jung Pan, C. Forsmark, P. Draganov, 2008, Gastrointestinal endoscopy.

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

J. Chan, D. Rockey, P. Thuluvath, 2020, Journal of hepatology.

Impaired function of CD4+/CD25+ T regulatory lymphocytes characterizes the self‐limited hepatitis A virus infection

L. Racioppi, O. Perrella, A. Perrella, 2008, Journal of gastroenterology and hepatology.

Retreating chronic hepatitis C with daily interferon alfacon‐1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

T. Hassanein, B. Bacon, P. Kwo, 2009, Hepatology.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

K. Reddy, D. Nelson, H. Vargas, 2016, Gastroenterology.

STAT-C: New therapies cannot get here fast enough

D. Nelson, G. Morelli, 2009 .

Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study

C. Stedman, M. Shiffman, E. Gane, 2016 .

A PUTATIVE RAB GTPASE-ACTIVATING PROTEIN BINDS HEPATITIS C VIRUS NS5A AND MEDIATES VIRAL REPLICATION

Hwang, T. Hassanein, H. Um, 2006 .

O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience

M. Manns, A. Bisceglie, G. Everson, 2015 .

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.

M. Manns, A. Lok, K. Reddy, 2020, Journal of hepatology.

Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network

K. Reddy, N. Terrault, P. Kwo, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen

C. Stedman, M. Shiffman, E. Gane, 2017, Hepatology.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

K. Reddy, T. Hassanein, K. Agarwal, 2018, Kidney international reports.

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study

Brian L. Pearlman, A. Lok, D. Nelson, 2021, Hepatology.

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection

N. Terrault, D. Nelson, J. Reeves, 2018, Scientific Reports.

Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution

L. Racioppi, P. Conti, O. Perrella, 2006, Gut.